Press Releases

New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
March 15, 2023
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 14, 2023
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
February 2, 2023
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
January 24, 2023
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
January 24, 2023
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
Dan Calkins

Investor Relations
781-469-1694
dcalkins@verastem.com

Nate LiaBraaten

Argot Partners
+1 212-600-1902
nate@argotpartners.com

Investor Kit
img